系统性硬化症相关雷诺现象与指端溃疡临床试验核心领域集的候选领域识别
OMERACT硬皮病血管疾病工作组通过三轮德尔菲法,在国际患者和临床医生中识别系统性硬化症相关雷诺现象(SSc-RP)和指端溃疡(SSc-DUs)临床试验的核心结局领域。SSc-RP有9个领域、SSc-DUs有16个领域达到共识(患者和其他参与者组中≥70%评为「至关重要」),其中多个生活影响领域为两种血管表现所共有。
要点
- SSc-RP核心领域包括病理生理表现3个和生活影响6个。
- SSc-DUs核心领域包括病理生理表现5个、生活影响7个和资源使用4个。
- 两种血管表现共有多个生活影响核心领域。
核心结论
- 患者与临床医生共同识别了SSc相关RP和DUs临床试验的核心领域,多个生活影响领域为两种血管表现共有,将用于制定最终核心领域集。
研究设计与样本
- 基于既往定性研究和系统文献综述的候选领域,分别对SSc-RP和SSc-DUs进行独立德尔菲调查。
- 通过国际患者倡导组织和临床网络邀请SSc患者及其他参与者(有治疗SSc患者和/或开展临床试验经验的临床医生)参与。
- 核心领域定义为三轮德尔菲后患者组和其他参与者组均≥70%评为「至关重要」的领域。
主要发现
- SSc-RP三轮德尔菲由来自39个国家的78例患者和116名其他参与者完成。
- SSc-DUs三轮德尔菲由来自36个国家的26例患者和99名其他参与者完成。
- SSc-RP有9个领域达到共识:病理生理表现核心区3个,生活影响核心区6个。
- SSc-DUs有16个领域达到共识:病理生理表现核心区5个,生活影响核心区7个,资源使用区4个。
关键数值与推荐
- 核心领域共识标准为三轮德尔菲后患者组和其他参与者组均≥70%评为「至关重要」。
- SSc-RP共识核心领域共9个(病理生理表现3个、生活影响6个)。
- SSc-DUs共识核心领域共16个(病理生理表现5个、生活影响7个、资源使用4个)。
临床怎么用
- 为SSc相关RP和DUs临床试验选择结局指标时,可参考这些共识核心领域。
- 关注生活影响领域在两种血管表现中的共性,有助于统一评估患者报告结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The OMERACT Scleroderma Vascular Disease Working Group sought to identify essential core outcome domains for inclusion in clinical trials focusing on Raynaud's phenomenon (RP) and/or digital ulcers (DUs) related to systemic sclerosis (SSc). METHODS: Candidate domains identified from previous qualitative work and systematic literature reviews were included in separate Delphi exercises for SSc-RP and SSc-DUs. Patients with SSc and other participants (clinicians with experience in treating patients with SSc and/or conducting clinical trials) were invited to participate through international patient advocacy groups and clinical networks. Core domains were defined as the domains reaching group consensus agreement (≥ 70% ratings of 'critical' in both patient and other participant groups) after three rounds of the Delphi. RESULTS: The 3-round Delphi exercises were completed by 78 patients and 116 others from 39 countries for SSc-RP, and by 26 patients and 99 others from 36 countries for SSc-DUs. For SSc-RP, nine domains reached consensus agreement as critically important: three domains in the Pathophysiological Manifestations core area and six in the Life Impact core area. For SSc-DUs, 16 domains reached consensus: five domains in the Pathophysiological Manifestations core area, seven in the Life Impact core area, and four in the Resource Use area. CONCLUSION: Patients with SSc and clinicians identified core domains for use in clinical trials in SSc-associated RP and DUs, with several Life Impact domains common to both vascular manifestations of disease. These results will inform development of a final Core Domain Set for use in clinical trials.
引用
- Proudman SM, Hughes M, Maltez N, et al. Identifying candidate core domains for clinical trials in systemic sclerosis-associated Raynaud's phenomenon and digital ulcers. Semin Arthritis Rheum. 2026. PMID: 42269228. doi:10.1016/j.semarthrit.2026.153009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。